Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...

The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...